Pharmac's cardiovascular team recommends funding Wegovy

Pharmac's cardiovascular team has recommended that Wegovy be funded for specific patient groups in New Zealand. The medication is currently available but unfunded, meaning patients must pay out of pocket.

Wegovy is a medication that assists with weight management and is already in use by many patients in New Zealand. If approved for funding, this would alleviate the financial burden on those requiring the drug to manage their cardiovascular health effectively.

The recommendation from the cardiovascular team reflects ongoing efforts to improve access to essential medications. This move aims to support individuals whose health could significantly benefit from the use of Wegovy, particularly in managing obesity-related conditions.

Public feedback on the recommendation will be gathered before any final decisions are made regarding funding. The outcome could have positive implications for many Kiwis seeking effective treatment options.

Originally reported by RNZ New Zealand Headlines.